The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple ...
AZoLifeSciences on MSN18h
A Closer Look at CAR T-Cell Therapy — Successes, Challenges, And FutureT-cell therapy is a revolutionary immunotherapy approach in which T cells are genetically modified to express a receptor that ...
The process begins with the collection of a patient’s T cells. Then these T cells are genetically modified to express ...
Chardan Capital analyst Geulah Livshits reiterated a Buy rating on CARGO Therapeutics, Inc. (CRGX – Research Report) today and set a ...
These findings suggest that KIR2DS2-positive (KIR2DS2+) natural killer (NK) cells could be an attractive therapeutic target ...
A recent meta-analysis investigating cardiovascular complications in adults undergoing chimeric antigen receptor (CAR) T-cell ...
MedPage Today on MSN6d
Overcoming the Challenges of Applying CAR T-Cell Therapy to Solid TumorsOpens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window ...
Ludwig Cancer Research scientists have devised new types of chimeric antigen-receptor (CAR) T cells—a type of cancer immunotherapy—that can be switched on to varying degrees of intensity and ...
INT2104 is a novel in vivo chimeric antigen receptor (CAR) gene therapy designed to generate CAR-T and CAR-NK cells in the patient’s body to target CD20-expressing malignant B cells Interim ...
News Medical on MSN8d
Modulating CD39 expression to enhance CAR-T cell therapy against hepatocellular carcinomaIn the quest to enhance the efficacy of chimeric antigen receptor T (CAR-T) cell therapy against hepatocellular carcinoma (HCC), a recent study has identified a pivotal role for CD39 expression in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback